Emergent BioSolutions Form 4: Director Disposes 7,086 Shares via 10b5-1

Rhea-AI Filing Summary

Kathryn C. Zoon, a director of Emergent BioSolutions, reported the sale of 7,086 shares of Emergent common stock on 08/15/2025 at an exact price of $8.87 per share. After the transaction she beneficially owned 71,799 shares. The filing states the shares were sold under a Rule 10b5-1 trading plan dated May 16, 2025 to satisfy tax obligations arising from RSU vesting on May 22 and May 25, 2025. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating pre-established trading parameters and potential compliance with insider trading rules
• Sale explicitly tied to RSU tax obligations, providing a clear and non-speculative rationale for the disposition
• Timely disclosure via Form 4 with signature executed on 08/18/2025

Negative

• Reduction in insider holdings by 7,086 shares, decreasing beneficial ownership to 71,799 shares

Insights

Financial Analyst

TL;DR Director sold 7,086 shares under a 10b5-1 plan to cover RSU tax obligations; transaction appears routine and disclosed.

The sale of 7,086 shares at $8.87 per share reduced the reporting person’s beneficial holding to 71,799 shares. The transaction was executed under a 10b5-1 plan dated May 16, 2025, which provides an affirmative defense against insider trading claims when conditions are met. From an investor-impact perspective, this is a common liquidity/tax-driven transaction rather than an operational signal. The disclosed facts show clear compliance and timely reporting.

Corporate Governance Expert

TL;DR Sale conducted under an established 10b5-1 plan to satisfy tax liabilities from RSU vesting; governance procedures followed.

The Form 4 specifies that the sale was pursuant to a written 10b5-1 plan, dated May 16, 2025, and explicitly ties the disposition to tax obligations from RSU vesting on May 22 and May 25, 2025. The use of a pre-established trading plan and the clear explanation in the filing align with best-practice executive trading disclosures. There is no additional information in the filing suggesting atypical governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zoon Kathryn C

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025	08/15/2025	S		7,086(1)	D	$8.87(2)	71,799	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on May 22, 2025 and May 25, 2025, respectively.

2. All shares sold at an exact price of $8.87.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Emergent BioSolutions director Kathryn C. Zoon sell?

She sold 7,086 shares of Emergent BioSolutions common stock at $8.87 per share on 08/15/2025.

Why were the shares sold by Kathryn C. Zoon?

The filing states the shares were sold pursuant to a Rule 10b5-1 trading plan dated May 16, 2025 to satisfy tax obligations from RSU vesting on May 22 and May 25, 2025.

How many shares does Kathryn C. Zoon beneficially own after the sale?

Following the reported transaction she beneficially owned 71,799 shares.

When was the Form 4 filed or signed?

The Form 4 shows a signature by an attorney-in-fact on 08/18/2025 reflecting the reported transaction dated 08/15/2025.

Was the sale at a specific price?

Yes, the filing reports all shares were sold at an exact price of $8.87 per share.